Novogen Ltd Ads (NVGN) 1.83 $NVGN Novogen Patent

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Novogen Ltd Ads (NVGN) 1.83 $NVGN

Novogen Patent Covering Anisina(TM) Has Proceeded to Grant
PR Newswire - Tue Jun 14, 6:00AM CDT
US-Australian drug discovery company Novogen Ltd (ASX: NRT; NASDAQ: NVGN) today announced that a patent for the ATM-3500 series had been granted in Australia. The ATM-3500 series includes the investigational agent known as Anisina (ATM-3507).
NVGN: 1.83 (-0.03)

Novogen Provides Update On Development Of Cantrixil
PR Newswire - Mon May 02, 6:00AM CDT
US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today provided an update on progress regarding the development of Cantrixil (TRXE-002-1), its lead superbenzopyran (SBP) molecule, which is intended for the treatment of ovarian cancer.
Q: 78.61 (+0.97), NVGN: 1.83 (-0.03)

Novogen Receives R&D Tax Incentive Cash Refund
PR Newswire - Wed Mar 16, 9:02PM CDT
US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced that it has received a cash refund of $2.8M from the Australian Taxation Office under the R&D Tax Incentive Program for the financial year ending 30 June 2015. This will support the Company's preparations to progress Cantrixil (TRXE-002-1), its lead superbenzopyran (SBP) drug candidate, to Phase 1 clinical trial in 2016.
NVGN: 1.83 (-0.03)

TapImmune Tackles Ovarian Cancer in Fast Track Phase II Clinical Trials
ACCESSWIRE - Tue Feb 09, 8:00AM CST
Fast Track Label and Orphan Drug Designation granted for Ovarian cancer indication following positive data; Phase II trials in TPIV 200 with a partner brings TapImmune closer to a $111.9 billion cancer drug market
CERU: 2.89 (unch), MRK: 58.66 (unch), NVGN: 1.83 (-0.03), ATRA: 24.40 (+0.40), BMY: 76.19 (+1.38)

Novogen Announces Changes to the Board with New Chairman and Deputy Chairman Appointed
PR Newswire - Fri Feb 05, 1:20AM CST
Australian-US drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced today the appointment of a new Chairman, Mr John O'Connor, and new Deputy Chairman, Mr Bryce Carmine, effective immediately.
NVGN: 1.83 (-0.03)

Novogen appoints Dr James Garner as CEO
M2 - Thu Dec 10, 3:57AM CST
Drug company Novogen (ASX:NRT)( NASDAQ:NVGN) reported on Wednesday that it has appointed Dr James Garner as its chief executive officer and as a member of its board of directors.
NVGN: 1.83 (-0.03), NRT: 8.79 (-0.85)

Novogen Appoints Dr James Garner as Chief Executive Officer
PR Newswire - Wed Dec 09, 3:59PM CST
US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced the appointment of Dr James Garner as Chief Executive Officer. Dr Garner will take up the role on 1 February 2016, at which time he will be appointed to the Board of Directors of Novogen.
NVGN: 1.83 (-0.03)

Novogen Engages Contract Research Organisation to Conduct Cantrixil Phase 1 Clinical Trial
PR Newswire - Tue Nov 24, 6:00AM CST
-- Novogen engages Novotech as CRO for upcoming Phase 1 clinical study
NVGN: 1.83 (-0.03)

Novogen Patent Covering Cantrixil and Trilexium Accepted in Australia
PR Newswire - Thu Nov 12, 6:00AM CST
US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ: NVGN) today announced that a patent application covering two of its key lead superbenzopyran (SBP) drug candidates has been accepted in Australia.
NVGN: 1.83 (-0.03)

Novogen's patent for Cantrixil and Trilexium under SBP discovery programme accepted in Australia
M2 - Thu Nov 12, 3:31AM CST
Drug company Novogen Limited (ASX:NRT)(NASDAQ:NVGN) disclosed on Wednesday the acceptance of its patent application covering two of its key lead superbenzopyran (SBP) drug candidates in Australia.
NVGN: 1.83 (-0.03), NRT: 8.79 (-0.85)

Preclinical Studies Justify Mode of Delivery and Dosing Regimen for Anisina
PR Newswire - Tue Nov 10, 4:34PM CST
US-Australian drug discovery company, Novogen Limited (NRT: ASX; NVGN: NASDAQ), today announced details of preclinical studies which confirm the efficacy of the lead anti-tropomyosin (ATM) compound, Anisina, when delivered using a clinically relevant formulation, mode of administration and dosing regimen.
NVGN: 1.83 (-0.03)

Novogen (NVGN) Conducts Scientific Review of R&D Program
Zacks Equity Research - Zacks Investment Research - Mon Aug 31, 1:20PM CDT
Novogen Limited (NVGN) announced results from a comprehensive scientific review of its research and development programs.
VRX: 20.89 (-1.41), ADHD: 4.31 (+0.03), UTHR: 125.08 (+4.07), NVGN: 1.83 (-0.03)

BUYINS.NET: NVGN, PSCE Removed From Naked Short Lists Today
M2 - Fri Aug 07, 10:40AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been After the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Novogen Ltd (NASDAQ:NVGN), Powershares S & P Small Cap Energy Portfolio (NASDAQ SCE). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
NVGN: 1.83 (-0.03), PSCE: 14.97 (-0.68)

Newly Appointed Acting CEO Outlines Immediate Plans for Novogen
PR Newswire - Wed Jul 29, 6:54PM CDT
US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today confirmed it is committed to progressing its ground-breaking technology platforms to Phase 1 clinical trials as soon as practicable and to ensure the Company delivers the best value for shareholders.
NVGN: 1.83 (-0.03)

Novogen Appoints Iain Ross as Acting CEO and Re-appoints Him to the Board
PR Newswire - Wed Jul 22, 6:00AM CDT
Novogen Limited (ASX:NRT; NASDAQ: NVGN), a US-Australian drug development company, today announced the appointment to the Board of Iain Ross, an experienced multi-national pharmaceutical and biotechnology executive. Mr Ross, a former director of Novogen Limited will re-join the Board with immediate effect and take on the role of Acting Chief Executive until a permanent appointment is made.
NVGN: 1.83 (-0.03)

Anisina awarded orphan drug designation from US FDA for Anisina for treating Neuroblastoma
M2 - Fri Jul 17, 3:21AM CDT
Drug company Novogen (Nasdaq:NVGN) reported on Thursday the receipt of the US Food and Drug Administration's (FDA) orphan drug designation for its chemotherapy candidate drug, Anisina, for neuroblastoma, a cancer that is most frequently observed in the young and the most common solid tumour in children outside the brain.
NVGN: 1.83 (-0.03)

Anisina Receives Orphan Drug Designation from FDA for Neuroblastoma
PR Newswire - Thu Jul 16, 6:30AM CDT
US-Australian drug discovery company, Novogen Limited, today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that its chemotherapy candidate drug, Anisina, has been granted Orphan Drug Designation for neuroblastoma.
NVGN: 1.83 (-0.03)

Pre-clinical Studies Suggest Anisina May Improve Chemotherapy Effectiveness in Childhood Cancer
PR Newswire - Mon Jul 13, 3:30PM CDT
US-Australian drug discovery company, Novogen Limited (NRT: ASX; NVGN: NASDAQ), today announced details of an in vivo proof of concept study that demonstrates their lead anti-tropomyosin drug candidate, Anisina, has the potential to improve the effectiveness of chemotherapy in children and reduce life-long side-effects.
NVGN: 1.83 (-0.03)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Africa Tech Festival 2026: A Digital Turning Point

Updated Category News Views 109

Setting the Stage for Digital Advancement in Africa Come mid-November, Cape Town's gonna be buzzing with the clatter of tech titans and financial honchos making their annual pilgrimage to the Africa Tech Festival. This ain't just a conference shindig—with names like Naspers, MTN, Meta, and Amazon on the docket, it's a darn convention shaping the continent's future...

Continue Reading
NVIDIA Faces Turbulent Storm with CEO Resignation

Updated Category News Views 81

Huang's Unexpected Exit and NVIDIA's Rocky Road Well, talk about drama in Silicon Valley. When executives start stumbling, it's not just some PR nightmare—it's a full-on crisis. NVIDIA's co-founder and CEO Jensen Huang is calling it quits, and not on some smooth, idyllic note. No, this is the kind of exit that investors dread. You’ve got affairs, security concerns,...

Continue Reading
Priceline's Cyber Week: A Pocket-Friendly Travel Bonanza

Updated Category News Views 178

Unpacking Priceline's Cyber Week Bonanza Alright, folks, grab your booking hats because Priceline is back with its annual Cyber Week extravaganza, aiming to give travelers a shot in the arm of savings just when inflation has everyone pinching pennies. From November 16 through December 2, Priceline rolls out the red carpet for vacation planners, offering eye-popping...

Continue Reading
BETR's Legal Tangle: A Deeper Dive into Investor Turmoil

Updated Category News Views 52

BETR's Shaky Ground: When Promises Fall Short In the rough-and-tumble world of finance, there's little room for empty promises. Better Home & Finance Holding Company (NASDAQ: BETR) might have to learn that the hard way. Investors who snagged shares between March 13 and August 6, 2026, are now clutching their heads as they watch their investments nosedive. When companies...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 187

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
Rock & Roll Hall of Fame's 2026 Induction Triumph

Updated Category News Views 116

A Night of Unstoppable Talent The Rock & Roll Hall of Fame's 2026 Induction Ceremony and boy, what a spectacle it was. Held on a lively Saturday night, November 14, in Los Angeles, it wasn't just an event; it was an electrifying testament to music's profound impact. With the grand ceremony kicking off at the historic city of stars, this year's induction turned the dial to...

Continue Reading
ISC2 Launches AI Security Academy for Cyber Pros

Updated Category News Views 147

AI-Driven Threats Demand Expert Attention Every corner of the tech world has been blabbering about AI, but when it comes to cybersecurity, it's a whole different beast entirely. ISC2—a nonprofit that I like to think of as the cyber wizards’ guild—just threw a lifeline to cybersecurity folks who are swimming in the deep end of AI. With their shiny new AI Security...

Continue Reading
Kinross Gold Fraud Lawsuit: What Shareholders Need to Know

Updated Category News Views 58

Kinross Gold's Legal Quagmire There's a fresh storm brewing for Kinross Gold Corporation (NYSE: KGC), and it ain't the kind investors enjoy riding. You see, the company is up to its neck in a class action lawsuit, courtesy of Schall, Brown & Schwartz LLP—a big-name shareholder rights litigation outfit. The gripe? Alleged securities fraud, violating §§10(b) and 20(a)...

Continue Reading
Mining Equipment Market to Surge, Hitting $42.81B by 2033

Updated Category News Views 136

Forecasts on Market Growth: A Robust Climb Ahead Brace yourself because this mining equipment racket is ramping up like you wouldn't believe. Analysts are telling us the market's supposed to roar from a $28.42 billion check in 2026 to a jaw-dropping $42.81 billion come 2033. That's a 6.0% CAGR—a figure that'll catch the eye of anyone not sound asleep at the wheel....

Continue Reading
Parallels Desktop Tops 2026 Picks for Windows on Mac

Updated Category News Views 84

Diving into the Cross-Platform Conundrum Now, I've been in the trenches long enough to know that when companies start relying on Mac computers but can't ditch their essential Windows apps, they're bound to hit a digital brick wall. Picture this—accounting, enterprise management, all that jazz that still needs Windows to function. For those jumping between these two...

Continue Reading

Top 5 Most Recently Viewed Articles

Sanoma Corporation's Recent Share Buyback Explained

Updated Category News Views 173

Insights into Sanoma Corporation's Share Buyback Activity Sanoma Corporation has conducted a significant share buyback, underscoring its commitment to enhancing shareholder value. These transactions were announced through a stock exchange release, giving investors an insightful look into the company's market activities. Details of the Buyback Transaction On a noteworthy...

Continue Reading
Finland's Real Estate Market Thrives in 2025: Key Insights

Updated Category News Views 248

The Resurgence of Finland's Real Estate Market Finland's real estate market is experiencing an inspiring recovery, marked by increasing transaction volumes and growing investment liquidity. This positive trend not only showcases renewed confidence among local investors but also reflects heightened interest from international players in the Finnish market. Analysts predict...

Continue Reading
Investors Alert: Join the Fight for Justice with aTyr Pharma

Updated Category News Views 190

Understanding the aTyr Pharma Situation Investors of aTyr Pharma Inc. are facing a challenging and distressing time following recent revelations regarding the company’s performance. The company is known for its innovative approaches in the realm of pharmaceuticals and has garnered significant attention in the stock market. However, the recent downturn in share value has...

Continue Reading
Fly Play hf. Reports Q2 Losses Amid External Challenges

Updated Category News Views 143

Profit Warning for Fly Play hf. Recently, Fly Play hf. shared concerns regarding its upcoming Q2 2025 interim financial report. The company anticipates that their results will fall short of last year’s performance and internal expectations. A net loss of around USD 16 million is projected for this quarter, compared to a loss of USD 10 million during the same period last...

Continue Reading
Olin Corporation Faces Challenges Amid Earnings Report

Updated Category News Views 85

Olin Corporation Reports Disappointing Third Quarter Earnings Olin Corporation (NYSE: OLN) recently announced its earnings for the third quarter of 2024, revealing significant challenges that led to a 14% drop in its stock price. This downturn was driven primarily by the fallout from Hurricane Beryl and a decline in demand within its ammunition division. Financial...

Continue Reading